Tag: Lenacapavir
-
Global Life Expectancy Rebounds After COVID Dip, Yet Mental Health and NCDs Loom
Global Life Expectancy Rebounds in 2023 Global life expectancy rose again in 2023 after a pandemic-era decline, with the latest Global Burden of Disease (GBD) study from the Institute for Health Metrics and Evaluation (IHME) showing overall life expectancy now roughly 20 years higher than in 1950. The findings, released at the World Health Summit…
-
Lenacapavir PrEP Price Drop: From $28,000 to $40 Expands Access
What is Lenacapavir and how does it work as PrEP? Lenacapavir is a long-acting HIV prevention drug (PrEP) that is administered as an injection twice a year. In the European Union, it has been approved for preventive use under the brand name Yeytuo, with Gilead as the manufacturer. Early studies have shown near-total protection against…
-
Lenacapavir: HIV prevention price slashed for LMICs
What is Lenacapavir and why does it matter for HIV prevention? Lenacapavir, marketed under the brand name Yeytuo, is a long-acting HIV prevention treatment that is injected twice a year. The EU approval placed it among the few options designed to simplify and strengthen pre- exposure prophylaxis (PrEP) by reducing the burden of daily pills.…
-
HIV Prevention Breakthrough: Lenacapavir PrEP Price Drop Expands Global Access
Lenacapavir: A Breakthrough in HIV Prevention Lenacapavir, marketed as Yeytuo, has advanced HIV prevention by offering a long-acting injectable PrEP treatment. Unlike daily pills, it is given as an injection twice a year, a feature that could simplify adherence for many people at risk. In the European Union, lenacapavir has been approved as a preventive…
-
Lenacapavir Agreement to Revolutionize HIV Prevention in LMICs
Lenacapavir: A Game-Changer in HIV Prevention On September 24, 2025, an unprecedented partnership was announced that promises to transform HIV prevention in low- and middle-income countries (LMICs). Dr. Reddy’s Laboratories has entered into a landmark agreement with Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI to make the injectable HIV prevention tool lenacapavir…
-
Lenacapavir Agreement: A Breakthrough in HIV Prevention
Introduction to Lenacapavir In a groundbreaking development for global health, a new injectable HIV prevention tool, lenacapavir, is set to be available at an astonishingly low price of just US$40 per year in 120 low- and middle-income countries (LMICs). This significant milestone comes as part of a landmark agreement announced on September 24, 2025, involving…
-
Revolutionary HIV Prevention: Lenacapavir Made Affordable
Introduction to Lenacapavir On September 24, 2025, a landmark agreement was reached to bring the groundbreaking HIV prevention tool, injectable lenacapavir, to 120 low- and middle-income countries (LMICs) at an astonishing cost of just $40 per year. This partnership between Dr. Reddy’s Laboratories, Unitaid, the Clinton Health Access Initiative (CHAI), and Wits RHI marks a…